MA45498A - Cellules treg génétiquement modifiées - Google Patents

Cellules treg génétiquement modifiées

Info

Publication number
MA45498A
MA45498A MA045498A MA45498A MA45498A MA 45498 A MA45498 A MA 45498A MA 045498 A MA045498 A MA 045498A MA 45498 A MA45498 A MA 45498A MA 45498 A MA45498 A MA 45498A
Authority
MA
Morocco
Prior art keywords
genetically modified
treg cells
modified treg
cells
genetically
Prior art date
Application number
MA045498A
Other languages
English (en)
Inventor
Takatoshi Chinen
Alexander Y Rudensky
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MA45498A publication Critical patent/MA45498A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
MA045498A 2016-06-16 2017-06-15 Cellules treg génétiquement modifiées MA45498A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351104P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45498A true MA45498A (fr) 2019-04-24

Family

ID=60663377

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045498A MA45498A (fr) 2016-06-16 2017-06-15 Cellules treg génétiquement modifiées

Country Status (8)

Country Link
US (1) US20190322983A1 (fr)
EP (1) EP3472305A4 (fr)
JP (2) JP2019518460A (fr)
CN (1) CN109415698A (fr)
AU (1) AU2017285319A1 (fr)
CA (1) CA3027546A1 (fr)
MA (1) MA45498A (fr)
WO (1) WO2017218850A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098202B2 (en) * 2016-10-10 2024-09-24 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
WO2019178518A1 (fr) * 2018-03-16 2019-09-19 The Regents Of The University Of California Modification de domaine de signalisation cellulaire dans des lymphocytes t régulateurs modifiés par un récepteur antigénique chimérique
WO2020014209A1 (fr) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Compositions de fusosomes et utilisations associées
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020102503A2 (fr) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Compositions de fusosome pour administration à des lymphocytes t
BR112021014442A2 (pt) * 2019-02-01 2021-09-21 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imunoterapia aprimorada
EP3997212B1 (fr) 2019-07-09 2026-03-18 The Children's Mercy Hospital Lymphocytes t régulateurs modifiés
US20230060230A1 (en) * 2020-01-27 2023-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Hdac6-inhibited human regulatory t cells
US20230138428A1 (en) * 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
EP4403580A1 (fr) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 récepteur antigénique chimérique
TW202436337A (zh) 2023-01-23 2024-09-16 漢諾威醫學院 嵌合抗原受體
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
EP4420676A1 (fr) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Récepteur antigénique chimérique
EP4669343A1 (fr) 2023-02-24 2025-12-31 Medizinische Hochschule Hannover Récepteur antigénique chimérique
EP4680728A1 (fr) 2023-03-17 2026-01-21 Quell Therapeutics Limited Thérapie treg
EP4434539A1 (fr) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Récepteur antigénique chimérique
CN121586582A (zh) 2023-03-20 2026-02-27 汉诺威医学院 嵌合抗原受体
WO2026008994A1 (fr) 2024-07-04 2026-01-08 Quell Therapeutics Limited Construction d'expression
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes
WO2008157394A2 (fr) * 2007-06-13 2008-12-24 La Jolla Institute For Allergy And Immunology Lymphocytes t régulateurs et procédé pour les préparer et les utiliser
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
EP3151854B1 (fr) * 2014-06-06 2020-02-26 Memorial Sloan Kettering Cancer Center Récepteurs d'antigènes chimères à mésothéline ciblée et leurs utilisations
JP2017519502A (ja) * 2014-06-17 2017-07-20 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ１２３特異的多重鎖キメラ抗原受容体
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Also Published As

Publication number Publication date
CA3027546A1 (fr) 2017-12-21
JP2019518460A (ja) 2019-07-04
EP3472305A1 (fr) 2019-04-24
AU2017285319A1 (en) 2018-12-20
US20190322983A1 (en) 2019-10-24
CN109415698A (zh) 2019-03-01
EP3472305A4 (fr) 2020-01-15
WO2017218850A1 (fr) 2017-12-21
JP2022058995A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
EP3472305A4 (fr) Cellules treg génétiquement modifiées
IL262772A (en) Genetically engineered cells and methods of making the same
NO2025012I1 (no) Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)
EP3562492A4 (fr) Cellules tueuses naturelles génétiquement modifiées
IL292828A (en) Central memory t cells for adoptive t cell therapy
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
IL259586B (en) Genetically modified stem cells and uses thereof
IL262359A (en) Ex vivo bite-activated t cells
EP3471772A4 (fr) Compositions et méthodes de déplétion de cellules
EP3858365C0 (fr) Lymphocytes t car optimisés avec de l'or
EP3411079A4 (fr) Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse
EP3507831A4 (fr) Cellules de mémoire et matrices mémoire
IL254734B1 (en) Modified t cells and methods of making and using the same
EP3507832A4 (fr) Cellules de mémoire et matrices mémoire
EP3443506C0 (fr) Neurone artificiel
EP4212613C0 (fr) Matrice de croissance cellulaire
EP3426690A4 (fr) Cellules effectrices immunes éditées par le génome
HUE053101T2 (hu) Javított T-sejt-készítmények
IL249970B (en) Gamma delta t cells and uses thereof
EP3475413C0 (fr) Lymphocytes t génétiquement modifiés
EP3573464A4 (fr) Ingénierie de cellules b
IL261710A (en) Production of antigen-specific t-cells
EP3455344A4 (fr) Cellules souches/progénitrices hématopoïétiques
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
EP3475986A4 (fr) Interconnexion cellule-à-cellule